Press release
Multiple Sclerosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medications, Treatment Market, Therapies, Statistics, MOA, ROA and Companies by DelveInsight
Multiple Sclerosis Clinical Trials
(Albany, USA) DelveInsight's Multiple Sclerosis Pipeline report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Multiple sclerosis pipeline landscape.
"Multiple sclerosis Pipeline Insight, 2024" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Multiple sclerosis pipeline landscape is provided which includes the disease overview and Multiple sclerosis treatment guidelines. The assessment part of the report embraces, in depth Multiple sclerosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Request a sample and discover the recent advances in Multiple Sclerosis Treatment Drugs @ Multiple Sclerosis Pipeline Outlook [https://www.delveinsight.com/report-store/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Multiple Sclerosis Pipeline Report
* DelveInsight's Multiple Sclerosis pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Multiple Sclerosis treatment.
* The leading companies working in the Multiple Sclerosis Market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
* Promising Multiple Sclerosis Pipeline Therapies in the various stages of development rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others.
* In November 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Ocrelizumab and Fingolimod. This double-blind, study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
* October 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ocrelizumab. This double-blind, study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
* September 2023: ImStem Biotechnology announced a study of phase 1 clinical trials for IMS001. This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.
Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, Visit @ Multiple Sclerosis Treatment Market [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Multiple Sclerosis Overview
Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, specifically the brain and spinal cord. It occurs when the immune system mistakenly attacks the protective myelin sheath covering nerve fibers, leading to communication problems between the brain and the rest of the body. Over time, the disease can cause permanent damage or deterioration of the nerves themselves.
Multiple sclerosis manifests in various forms, with relapsing-remitting Multiple sclerosis (RRMS) being the most common. RRMS is characterized by episodes of new or worsening symptoms (relapses) followed by periods of partial or complete recovery (remissions). Other types include primary progressive Multiple sclerosis (PPMS), which involves steady progression without relapses, and secondary progressive Multiple sclerosis (SPMS), which follows an initial relapsing-remitting course and then transitions to a progressive form.
Symptoms of Multiple sclerosis vary widely and can include fatigue, numbness or tingling, muscle weakness, coordination and balance issues, vision problems, and cognitive changes. The exact cause of Multiple sclerosis remains unknown, though it is believed to result from a combination of genetic and environmental factors.
There is no cure for Multiple sclerosis, but treatments are available to manage symptoms, reduce relapses, and slow disease progression. These treatments include disease-modifying therapies, corticosteroids, physical therapy, and various medications to address specific symptoms. Early diagnosis and intervention are crucial for improving long-term outcomes.
Find out more about Multiple Sclerosis Therapeutics Assessment @ Multiple Sclerosis Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Multiple Sclerosis Emerging Drugs Profile
* Ublituximab: TG Therapeutics
* IMU-838: Immunic
* ATA188: Atara Biotherapeutics
* ANK-700: ANOKION
Multiple Sclerosis Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the Multiple sclerosis therapies. The Multiple sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.
DelveInsight's Multiple Sclerosis Pipeline Report covers around 100+ products under different phases of clinical development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Request for Sample Report @ Multiple Sclerosis Drugs Assessment [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Route of Administration
Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
Molecule Type
Multiple Sclerosis Products have been categorized under various Molecule types such as
* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type
Learn more about the emerging Multiple Sclerosis Pipeline Therapies @ Multiple Sclerosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/multiple-sclerosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Multiple Sclerosis Pipeline Report
* Coverage- Global
* Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
* Multiple Sclerosis Pipeline Therapies- HIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others
Table of Content
* Introduction
* Executive Summary
* Multiple sclerosis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Multiple sclerosis - DelveInsight's Analytical Perspective
* Late Stage Products (Preregistration)
* Ublituximab: TG Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* EHP 101: Emerald Health Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ASLAN 003: ASLAN Pharmaceuticals
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Lucid MS: FSD Pharma
* Drug profiles in the detailed report.....
* Inactive Products
* Multiple sclerosis Key Companies
* Multiple sclerosis Key Products
* Multiple sclerosis- Unmet Needs
* Multiple sclerosis- Market Drivers and Barriers
* Multiple sclerosis- Future Perspectives and Conclusion
* Multiple sclerosis Analyst Views
* Multiple sclerosis Key Companies
* Appendix
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=multiple-sclerosis-clinical-trials-2024-ema-pdma-fda-approvals-medications-treatment-market-therapies-statistics-moa-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Multiple Sclerosis Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medications, Treatment Market, Therapies, Statistics, MOA, ROA and Companies by DelveInsight here
News-ID: 3693637 • Views: …
More Releases from ABNewswire
Panhwar Jet Set to Launch One of the Most Anticipated Aviation IPOs in Decades
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXcZfPtIaxQkE15AbKDvtlAcCqPEotsULOV5dWBN0R9lZ6qYZdN1zLEAbUoBbl-xwoeHNYEgaQSHk3TAAZ4SAMwhbXoSUN5RbqVSMFxG380d8YoItj72i2yX0OCN0qa0SQ?key=kjvLxaZiafkw5p7fSPVtOw
While everyone's busy chasing flying taxis, one company is quietly reinventing cargo.
As electric aviation takes off, most of the industry's spotlight is on passenger eVTOLs and urban air mobility. But there's a less flashy, yet highly profitable frontier emerging: unmanned cargo delivery.
In the U.S. alone, over 4.6 million urgent deliveries under 20 pounds happen every single day-currently served by fuel-hungry ground transport and manned aircraft, both costly and carbon-intensive.
Enter…
Hajar travels Launches Premium Umrah Packages from California to Makkah with Umr …
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXfzD99yiCXSvWcRGrpaXmR5b-mUSErEJRihP1cxm9pbyVd4fhCzzH6AVVAGsuNz0ZvQq-CUgALF5CCuzz6TOxIB-sUKkXfwBW_asjYkp0WQsHHKkB_m4teUH4CcFo6wBuM?key=uXUoOG_dnNEWwz5eyS9xgQ
Every Muslim has a deeply moving spiritual and enduring memory of performing Umrah. The opportunity to perform Umrah occurs only once in human lifespan which provides believers with both faith strengthening experiences alongside intimate encounters with Allah. The residents of California face persistent overwhelming challenges while organizing their sacred pilgrimage due to the numerous logistical requirements. The complete Umrah arrangement is provided by Umrah Lodges through carefully designed packages…
Despite Growing Competition, eBay Remains a Scalable, Profitable Marketplace - M …
Image: https://lh7-rt.googleusercontent.com/docsz/AD_4nXcDhufKglqnxbRHtXGH5an1ttTpzhKjpin6LjL7aTkkmU8UQBowfiw4il6MxmZhNguqr43xc0z7LU_YFQXcaWR3MnX4fFbCbABMRgLq2JEt1rhW2tPVGWAL2A35V4vsOtikb-Kw-cOy0HrPKyyzmQU?key=DYSn1S8cLNH-zC2ECBy55g
As ecommerce giants continue to crowd the landscape, Mooka is reaffirming its belief in one of the internet's most enduring platforms: eBay. While newer marketplaces like TikTok Shop and Whatnot are generating buzz, Mooka has made it clear that eBay still offers massive untapped potential for third-party sellers - and that the right strategy and systems can unlock it.
Mooka, an ecommerce software company specializing in automation, compliance, and analytics,…
Australian Demand for Sustainable Period Care Surges, With my mimi Reporting Rec …
Australian consumers are rethinking how they manage their periods. While disposable pads and tampons once dominated, there's now a rapid shift towards sustainable, reusable options.
Recent research by the Burnet Institute found that 37% of young people aged 15 to 29 in Victoria used a reusable menstrual product during their last period - highlighting just how quickly sustainable solutions are gaining ground.
Image: https://www.abnewswire.com/upload/2025/05/94aa43033bec6f12f00b60a62cbbd903.jpg
Leading this change is Australian brand my mimi [https://mymimi.com.au/],…
More Releases for Multiple
Massive MIMO (Multiple-input multiple-output) Market 2022-2028 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Massive MIMO (Multiple-input multiple-output) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Massive MIMO (Multiple-input multiple-output) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Massive MIMO (Multiple-input multiple-output)…
Multiple Sclerosis Therapeutics Market – Increasing prevalence of multiple scl …
Multiple Sclerosis Therapeutics Market report is a exploration database spread across colorful runners with multiple tables and numbers in it. The exploration covers a precious source of perceptive information for business strategists. Multiple Sclerosis Therapeutics Industry provides the overview with growth analysis and literal & futuristic cost, profit, demand and force data (as applicable). The exploration judges give an elegant description of the value chain and its distributor analysis.
This comprehensive…
Global Multiple Sclerosis Market Size, Global Multiple Sclerosis Market Share, G …
The Global Multiple Sclerosis Market Size is majorly driven by the factors such as rising number of consolidations between the market players for exploring the untapped market opportunity across the world.
Request for Sample of This Research Report @ https://bit.ly/2Nh6b4d
Top Key Player:-
Hoffmann-La Roche Ltd.
Bayer Healthcare AG
Teva Pharmaceuticals
GlaxoSmithKline
AbbVie Inc.
Sonafi Pasteur
Pfizer Inc.
Merck & Company
Novartis AG
AB Science
Opexa
Multiple Sclerosis (MS) is a disease in which the insulating covers of nerves and spinal cord are…
Multiple Ion Beam Microscopes Market- Multiple Ion Beam Microscopes Have Huge Ap …
An ion beam is a kind of charged particle beam which consists of ions. With the advancement of nanotechnology new and advanced fabrication techniques are required which helps in production of functional features in much smaller scales. Advanced techniques are being used for applications in material science which uses image surfaces producing different features in a nanoscale. Gas field ion source technology has the capability of combining helium and neon…
Smart Antenna Market Report 2018: Segmentation by Type (Switched Beam Smart Ante …
Global Smart Antenna market research report provides company profile for Cobham Antenna Systems(Suffolk, United Kingdom), Intel Corp.( Santa Clara, California, United States), Samsung Electronics CoLtd. ( Seoul, South Korea), ArrayComm LLC ( California, United States), Alcatel-Lucent International Holdings Inc.( Paris, France), Motorola Solutions Inc.( Illinois, the U.S.) and Others.
This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017,…
Thermoseal Group Multiple Award Winners
For the second year in a row, Thermoseal Group is the winner of the coveted Glass and Glazing Industry’s G-Award for ‘Component Supplier of the Year’ as announced at the prestigious Gala Dinner held at the Hilton on Park Lane Hotel in London on Friday 18 November 2016.
This was a great day for Thermoseal Group who were also announced winners at two other awards events held that day…
